Telomir Pharmaceuticals, Inc. Common Stock (TELO) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -1.77M | -1.2M | -927.26K | -696.44K | -863.13K | -605.81K | -1M | -1.52M | -1.94M | -1.09M | -2M | -33.58K |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -105.47% | -98.3% | 7.49% | 54.27% | 55.5% | 44.28% | 49.96% | -4435.38% | -163.6% | -325.04% | - | - |
| Net Income | -990.95K | -2.06M | -1.1M | -5.07M | -2.18M | -2.9M | -5.93M | -1.45M | -6.25M | -9.33M | -1.71M | -1.55M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 1.38M | 2.06M | 4.81M | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 39.8K | -7.95K | 98.14K | 4.66M | -28.68K | 130K | 0 | 0 | 4.34M | 8.22M | 757.17K | 124.05K |
| Working Capital Changes | -822.37K | 867.79K | 76.89K | -291K | -30.32K | 100.53K | 123.13K | -73.84K | -23.35K | 23K | -1.05M | 1.39M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -257.15K | 207.39K | 74.42K | -303.9K | 0 | 81.06K | 112.67K | 0 | 74.74K | 22.75K | -1.05M | 0 |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 47.35K | 1.16M | 7.5M | 1.05M | 0 | 1.04M | -46.91K | 132.44K | 5.21M | 1.09M | 1.99M | 46.4K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | -132.44K | 132.44K | -101K | 1.83M | 1.56M | 487.91K |
| Equity Issued (Net) | 0 | 1M | 7.5M | 1.05M | 0 | 1.04M | 0 | 0 | 5.83M | 90K | 0 | -90K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 47.35K | 155.52K | 0 | 0 | 0 | 1 | 85.53K | 0 | -519.48K | -836.08K | 429.81K | -351.51K |
| Net Change in Cash | -1.73M | -42.63K | 6.57M | 351.32K | -863.13K | 431.49K | -1.05M | -1.39M | 3.27M | -1.22K | -12.18K | 12.82K |
| Free Cash Flow | -1.77M | -1.2M | -927.26K | -696.44K | -863.13K | -605.81K | -1M | -1.52M | -1.94M | -1.09M | -2M | -33.58K |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -105.47% | -98.3% | 7.49% | 54.27% | 55.5% | 44.28% | 49.96% | -4435.38% | -163.6% | -325.04% | - | - |
| FCF per Share | -0.05 | -0.03 | -0.03 | -0.02 | -0.03 | -0.02 | -0.03 | -0.05 | -0.07 | -0.04 | -0.07 | -0.00 |
| FCF Conversion (FCF/Net Income) | 1.79x | 0.58x | 0.84x | 0.14x | 0.40x | 0.21x | 0.17x | 1.05x | 0.31x | 0.12x | 1.17x | 0.02x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |